Trial Profile

Phase 2 clinical trial of DM199 for chronic kidney disease (CKD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jan 2020 New trial record
23 Jan 2020 According to a Catalent Biologics media release, On behalf of DiaMedica, Catalent has produced a cGMP batch of the drug at its Madison, Wisconsin facility to support the trial using its proprietary GPEx cell line development technology. DiaMedica intends to initiate participant enrollment in the clinical study in the next few weeks.
23 Jan 2020 According to a Catalent Biologics media release, DiaMedica Therapeutics has received U.S. Food and Drug Administration (FDA) approval to commence this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com